Latigo Biotherapeutics, Inc.
- Last sale
- Nov 12, 2026 · -4.52%
- Market cap
- $855.26M
- 66.3M shares
- Filings
- 46
—
—
—Q3 2026
—Q3 2026
—Q3 2026derived
—Q3 2026
—Q3 2026+287.5% FY25 yoy
- $855.26M
- —
- —
- 2.2×
- —
- —
FY2026 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
No annual history for this metric yet.
| Period | Ended | Value | Kind | Source trail |
|---|
Pharmaceutical preparations
Latigo Biotherapeutics, Inc. is the 153rd largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
PHARPharming Group N.V.$376.1M26.6%0.8%$922.0MCRVSCorvus Pharmaceuticals, Inc.———$895.4MAKTSAktis Oncology, Inc.———$879.8MORICOric Pharmaceuticals, Inc.———$879.0MRIGLRigel Pharmaceuticals Inc$294.3M64.1%124.7%$855.8M
LTGOLatigo Biotherapeutics, Inc. (this company)———$855.3M
LXRXLexicon Pharmaceuticals, Inc.$49.8M729.9%101.1%$812.6MIRWDIronwood Pharmaceuticals Inc$296.2M15.7%8.1%$801.3MALMSAlumis Inc.$24.1M—1,011.7%$796.5MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Latigo Biotherapeutics, Inc. · CIK 2056611 · Engraved from SEC EDGAR